Transcending chemotherapy regimen interactions with complementary and alternative medicines through 3G networks: OncoRx-MI for the mobile internet
Yap, Kevin Yi-Lwern, See, Cheng Shang, Chan, Alexandre and Chui, Wai Keung. (2010) Transcending chemotherapy regimen interactions with complementary and alternative medicines through 3G networks: OncoRx-MI for the mobile internet. Supportive Care In Cancer, Vo.18 (Suppl.3). S93-S93. ISSN 0941-4355Full text not available from this repository.
Official URL: http://dx.doi.org/10.1007/s00520-010-0891-0
Objectives: Cancer patients often use Complementary and Alternative Medicines (CAMs) to reduce chemotherapy side effects. Severe adverse reactions resulting from anticancer drug (ACD)-CAM interactions (DCIs) can occur in some cases, and failure to recognize these harmful DCIscan potentiate lethal side effects of ACDs, giving rise to negative therapeutic outcomes. The advent of 3G networks and newer handheld devices has enabled the development of various healthcare applications for the mobile internet (MI). However, there is currently no application available to detect DCIs of combination chemotherapy regimens (CRegs). We describe the development of OncoRx-MI, a first oncology-specific iPhone application for single- and multiple-agent CRegs.
Methods: Data regarding ACDs, CRegs and CAMs were
compiled from 5 hardcopy and 9 online resources, package inserts and published literature from Pubmed. The iPhone web application was designed using Adobe softwares and open-source scripts, and served through a third-party server. DCI searches are based on CReg acronyms. The application’s interface fits the iPhone screen resolution of 320x480 pixels, and follows a longitudinal format to improve usability.
Results: OncoRx-MI consists of a total of 256 CRegs which detects over 2500 CReg interactions with 166 CAMs classified into 8 categories. Majority of the DCIs are pharmacokinetic in nature (79%), involving the induction and inhibition of the cytochrome P450 isozymes (CYP2C9, 2C19, 2D6, 3A4) and p-glycoprotein. Pharmacodynamic HDIs include hepatotoxicity (39%), altered corticosteroid efficacies (30%), as well as increased risks of hypoglycemia (4%), hypertensive crisis (2%), bleeding, and serotonin syndrome (1% each).
Conclusions: OncoRx-MI is the first mobile web-based application of its kind which detects DCIs for combination
CRegs. OncoRx-MI will be continually updated to include
interactions with various drug classes. We hope that this
database is useful for managing chemotherapy interactions.
in daily clinical practice, and can ultimately improve
pharmaceutical care of cancer patients
|Item Type:||Journal Article|
|Subjects:||Q Science > QA Mathematics > QA76 Electronic computers. Computer science. Computer software
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Z Bibliography. Library Science. Information Resources > ZA Information resources > ZA4450 Databases
|Divisions:||Faculty of Science > WMG (Formerly the Warwick Manufacturing Group)|
|Journal or Publication Title:||Supportive Care In Cancer|
|Official Date:||June 2010|
|Number of Pages:||1|
|Access rights to Published version:||Restricted or Subscription Access|
|Version or Related Resource:||This item was originally presented as a poster at the 2010 International MASCC/ISOO Symposium, Vancouver, British Columbia, Canada, Jun 24-26, 2010.|
Actions (login required)